- Home
- LPRO vs KPTI Comparison
LPRO vs KPTI Comparison
Compare LPRO & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | KPTI |
|---|---|---|
| Founded | 2000 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 172.6M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LPRO | KPTI |
|---|---|---|
| Price | $1.35 | $8.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $2.83 | ★ $15.40 |
| AVG Volume (30 Days) | 451.8K | ★ 783.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | $306.66 | N/A |
| Revenue Next Year | $7.97 | $46.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $0.70 | $3.51 |
| 52 Week High | $4.79 | $10.99 |
Technical Indicators
Market Signals| Indicator | LPRO | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 53.29 |
| Support Level | $1.33 | $5.60 |
| Resistance Level | $1.96 | $8.95 |
| Average True Range (ATR) | 0.10 | 0.78 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 27.66 | 14.95 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).